Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Dual antiplatelet therapy improves outcomes in patients undergoing coronary stenting

Emmanouil S. Brilakis, M.D., Ph.D., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, and colleagues conducted a review of medical literature regarding optimal medical therapy after percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries).

10 Jul 2013

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Janssen Research & Development, LLC announced today results of an open label, single-center, parallel group study showing that a type of medication called prothrombin complex concentrates can reverse the blood thinning effects of XARELTO (rivaroxaban) in healthy subjects.

2 Jul 2013

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen Research & Development, LLC today announced the U.S. Food and Drug Administration has issued a complete response letter for the supplemental New Drug Application for XARELTO (rivaroxaban) to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

28 Jun 2013

Clinical study shows that clopidogrel not effective in infants with congenital heart diseases

One of the largest clinical trials done in infants with congenital (present at birth) heart diseases, published in the New England Journal of Medicine, shows that the increasingly common practice of using the drug clopidogrel (Plavix-) to reduce shunt-related blood flow issues is not effective in the dose studied.

21 Jun 2013

Faster, more potent antithrombotic drugs recommended for high-risk heart attack patients

The Cardiovascular Research Laboratory of the Bellvitge Biomedical Research Institute led by the cardiologist of the Bellvitge University Hospital Jos- Luis Ferreiro has conducted a study on the effect of antiplatelet drugs given to high risk patients suffering from acute myocardial infaction (heart attack) in the context of the Infarction Code.

6 Jun 2013

New AAN guideline provides direction for use of blood thinners during surgery

A new guideline from the American Academy of Neurology will help people who take blood thinners decide whether or not to take them during surgery or other medical procedures.

28 May 2013

University of Michigan Stroke Program study examines use of tPA in stroke patients

Millions of Americans take aspirin or other drugs every day to reduce their risk of heart attacks or other problems caused by blood clots.

14 Mar 2013

STREAM trial: Treatment with tenecteplase before hospital transfer benefits some

A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.

13 Mar 2013

Cangrelor solidly outperforms clopidogrel during percutaneous coronary intervention

The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the phase III CHAMPION PHOENIX study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

12 Mar 2013

Cangrelor more effective than clopidogrel in preventing blood clots

A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures.

12 Mar 2013

Tranexamic acid role in coronary bypass surgery

Tranexamic acid balances the increased bleeding risk associated with recent clopidogrel use in patients undergoing on-pump coronary artery bypass grafting, shows a randomized trial.

7 Mar 2013

WOEST supports clopidogrel only in PCI patients on anticoagulation

Publication of the WOEST trial results reaffirm the study’s major finding that antiplatelet therapy with clopidogrel alone is preferable to the use of both aspirin and clopidogrel in patients undergoing percutaneous coronary intervention who are receiving oral anticoagulant therapy.

25 Feb 2013

Clopidogrel pretreatment for PCI does not reduce risk of overall mortality

Among patients scheduled for a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), pretreatment with the antiplatelet agent clopidogrel was not associated with a lower risk of overall mortality but was associated with a significantly lower risk of major coronary events, according to a review and meta-analysis of previous studies published in the December 19 issue of JAMA.

19 Dec 2012

Antibody-coated stents carry increased risk of myocardial infarction and re-operation

If narrowed or blocked coronary vessels have to be widened or opened, a vascular support (stent) is usually inserted. Drug-coated stents are preferred for patients at high risk of renewed narrowing of vessels (restenosis). However, the use of antibody-coated stents has been increasing in recent years. Current studies provide indications that these new antibody-coated stents more frequently lead to myocardial infarction and make re-operation necessary.

15 Nov 2012

TRILOGY-ACS platelet function substudy results revealed

The platelet function substudy of the TRILOGY-ACS trial shows that there is no significant difference between prasugrel and clopidogrel in cardiovascular mortality, myocardial infarction, or stroke outcomes.

12 Nov 2012

Most patients taking common blood-thinning drugs may be receiving wrong dosage levels

Cardiology researchers at the Intermountain Medical Center Heart Institute have found that approximately 75 percent of patients taking two common blood-thinning drugs may be receiving the wrong dosage levels, according to a new study.

8 Nov 2012

Cause of heart attacks or strokes may be different in some patients treated with anti-platelet drugs

The cause of heart attacks or strokes among some patients treated with anti-platelet drugs may be different than for patients who have undergone surgical procedures to restore blood flow, according to researchers at Duke Medicine.

7 Nov 2012

Patients with diabetes, multi-vessel coronary artery disease can benefit from bypass surgery

An international, clinical research trial has shown that patients with diabetes whose multi-vessel coronary artery disease is treated with bypass surgery live longer and are less likely to suffer severe complications like heart attacks than those who undergo angioplasty.

6 Nov 2012

Study compares effectiveness of CABG surgery with PCI for adults with diabetes and heart disease

Adults with diabetes and multi-vessel coronary heart disease who underwent cardiac bypass surgery had better overall heart-related outcomes than those who underwent an artery-opening procedure to improve blood flow to the heart muscle, according to the results from an international study. The research was supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

5 Nov 2012

PFO closure with investigational device may prevent cryptogenic ischemic stroke

A clinical trial indicates that using an investigational medical device to close a PFO, or "hole in the heart," may be superior to medical management alone in the prevention of a repeated stroke.

26 Oct 2012